IMPACT OF METABOLIC SYNDROME ON DEVELOPMENT OF CASTRATION-RESISTANT PROSTATE CANCER
Kharkiv Medical Academy of Postgraduate Education, Ukraine
To date, prostate cancer, the mortality at which has increased by 16 % in recent decades, is considered one of the most socially significant oncological diseases in the world. Metabolic syndrome, a set of risk factors including obesity and insulin resistance, is widely thought to be implicated in development of prostate cancer. But its impact on androgen deprivation therapy (ADT) efficacy has not been studied. With this purpose we performed a retrospective investigation of 102 prostate cancer patients in whom MS was assessed at the time of initiation of ADT. The study end points were time to prostate−specific antigen (PSA) progression and overall survival from time of starting ADT. The results showed that mean period until PSA progression in patients with metabolic syndrome was 16 months, without it 36 months. The life expectancy of patients with metabolic syndrome made 36.5 months from ADT onset, while in patients without it was 46.7 months. This preliminary data suggest that MS is a risk factor for earlier development of castration−resistant prostate cancer and support the need for prospective evaluation of this finding.
Key words: prostate cancer, metabolic syndrome, androgen deprivation therapy, castration resistance.